Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | MAPT | P10636 | 9/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14774773 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774760 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774891 | 0.85 | ALDH1A1 (0.75) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774675 | 0.85 | ALDH1A1 (0.75) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774616 | 0.82 | ALDH1A1 (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774747 | 0.82 | ALDH1A1 (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774709 | 0.81 | ALDH1A1 (0.85) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774734 | 0.81 | ALDH1A1 (0.85) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL7662968 | 0.79 | ALDH1A1 (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL14774786 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | claimed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | claimed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | disclosed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP10 | ALDH1A1 2342/4885MAPT 4672/4885HPGD 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.